FDA Advisory Committees Would Get Patient Influence Under Hagan Bill
This article was originally published in The Tan Sheet
Adjusting advisory committee conflict of interest rules becomes a high-priority issue in reauthorizing FDA’s drug user fee program. With several bills proposing to loosen the rules, Sen. Hagan’s draft FDA reform legislation could bring the most changes.
You may also be interested in...
The first legislative salvos were launched last week in a battle that is sure to escalate in conjunction with device user fee reauthorization efforts next year.
With its recent hiring push drawing attention, FDA is quietly undertaking another recruitment effort - filling advisory committee roster vacancies
Two physicians experienced in agency affairs and operations, former commissioner David Kessler and former principal deputy commissioner Joshua Sharfstein, are reportedly finalists to head Biden’s FDA.